Evidence map›Paper›PMID 41132723›Full record

ArticleFrontiers in oncology2025

Case Report: Pemetrexed-induced pseudocellulitis: a rare adverse effect to be recognized for better management.

Emma Proux, Jeanne Chen, Caroline Bonhomme, Pierre Pottier, Marie Piroth

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emma Proux *Dermatology Department, University Hospital of Nantes, Nantes, France.
Jeanne ChenDepartment of Medical Oncology, University Hospital of Nantes, Nantes, France.
Caroline BonhommeDepartment of Internal Medicine, University Hospital of Nantes, Nantes, France.
Pierre PottierDepartment of Internal Medicine, University Hospital of Nantes, Nantes, France.
Marie Piroth *Dermatology Department, University Hospital of Nantes, Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudocellulitis, a non-infectious inflammatory reaction mimicking infectious cellulitis, is a rare and often underrecognized adverse reaction to pemetrexed, frequently diagnosed late and leading to inappropriate treatments, particularly unnecessary antibiotic use. Through the presentation of a new case and a literature review conducted using Scopus and PubMed, we aim to clarify its clinical presentation and management. We report a new case of pemetrexed-induced pseudocellulitis (PIP), initially misdiagnosed and treated unnecessarily with multiple antibiotics. Following the correct diagnosis, the patient was successfully treated with both oral and topical corticosteroids. Pemetrexed had to be discontinued. PIP clinically mimics cellulitis, presenting unilaterally or bilaterally, sometimes accompanied by fever and inflammatory syndrome. Its onset is variable, occurring either after the initial pemetrexed administration or following subsequent cycles, with no clear dose dependency. Skin biopsy is not essential for diagnosis. Management typically involves local and/or systemic corticosteroids. Discontinuation of pemetrexed should be evaluated on a case-by-case basis and is not always necessary. Improved recognition of this condition is essential to avoid unnecessary interventions, enhance patient care, and prevent long-term complications due to prolonged inflammation.

Indexed as

antifolatecellulitisdrug eruptionsdrug-inducedpemetrexedpemetrexed-induced pseudocellulitispseudocellulitis

Identifiers

PMID41132723
PMCPMC12540078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.